We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

zaterdag 28 oktober 2017

The Lancet: [Articles] Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres comp...

[Articles] Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial
In patients with locally advanced or intermediate-stage hepatocellular carcinoma after unsuccessful transarterial chemoembolisation, overall survival did not significantly differ between the two groups. Quality of life and tolerance might help when choosing between the two treatments.
Read more

[News] Ischaemia in liver resection predicts cancer-specific survival
Remnant liver ischaemia is predictive of decreased recurrence-free survival and cancer-specific survival in patients who have surgical resection for colorectal liver metastases, according to a recent study.
Read more

[Comment] Grant, deny, or reassess the role of yttrium-90 in hepatocellular carcinoma?
Transarterial chemoembolisation and selective internal radiotherapy (SIRT) with yttrium-90 (90Y) are viable treatment options for patients with unresectable, localised hepatocellular carcinoma, including selected patients with major vascular invasion. However, frontline sorafenib and second-line regorafenib are the only US Food and Drug Administration (FDA)-approved systemic therapy options available for patients with locally advanced (ie, with major vascular invasion) or metastatic hepatocellular carcinoma.
Read more

[Articles] Cancer incidence and mortality among young adults aged 20–39 years worldwide in 2012: a population-based study
The global cancer burden among 20–39 year-olds differs from that seen in younger or older ages and varies substantially by age, sex, development level, and geographical region. Although the cancer burden is lower in this age group than that observed in older ages, the societal and economic effects remain great given the major effects of premature morbidity and mortality. Targeted surveillance, prevention, and treatment are needed to reduce the cancer burden in this underserved age group.
Read more

[Comment] Reducing the global cancer burden among young adults
In The Lancet Oncology, Miranda M Fidler and colleagues1 provide estimates for cancer incidence and mortality among young adults (aged 20–39) worldwide. These estimates were categorised by country income and development level (Human Development Index, HDI), thus affording investigators the opportunity to compare across cancer types. This important study establishes a contemporary global burden of cancer in young adults—975 396 new cancer cases and 358 392 cancer-related deaths in 2012. The authors provide the foundation necessary for a call to action for clinicians, policy makers, and researchers focused on reducing the substantial burden that cancer afflicts upon young adults.
Read more